Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EED | O75530 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019761 | 1.00 | GRIN2B (0.40) | GRIN2BGRIN1MEN1KMT2AESR1 | |
| SCHEMBL4019987 | 0.92 | KMT2A (0.39) | GRIN2BMEN1KMT2AMAPK1EED | |
| SCHEMBL4019982 | 0.92 | KMT2A (0.39) | GRIN2BMEN1KMT2AMAPK1EED | |
| SCHEMBL4024477 | 0.90 | ABL1 (0.37) | GRIN2BGRIN1MEN1KMT2AEED | |
| SCHEMBL4026851 | 0.90 | KMT2A (0.44) | GRIN2BGRIN1MEN1KMT2A | |
| SCHEMBL4026855 | 0.90 | KMT2A (0.44) | GRIN2BGRIN1MEN1KMT2A | |
| SCHEMBL4024473 | 0.90 | ABL1 (0.37) | GRIN2BGRIN1MEN1KMT2AEED | |
| SCHEMBL4751835 | 0.89 | GRIN2B (0.41) | GRIN2BGRIN1MEN1KMT2AMAPK1 | |
| SCHEMBL4019577 | 0.89 | EED (0.37) | MEN1KMT2AMAPK1EED | |
| SCHEMBL4019575 | 0.89 | EED (0.37) | MEN1KMT2AMAPK1EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | GRIN2B 4170/4885GRIN1 4435/4885MEN1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.